Aquestive Therapeutics Inc

AQST shares surge 43% after FDA’s CRL for Anaphylm, showcasing investor optimism amid a planned resubmission and potential rapid review.

Explore how Aquestive Therapeutics’ late‑stage CNS drug pipeline and recent financial metrics paint a picture of risk and potential recovery for investors.

Discover how Aquestive Therapeutics’ new leadership, analyst upgrades, and upcoming FDA‑approved Anaphylm™ are shaping its stock and pipeline prospects.

Aquestive Therapeutics, a pharmaceutical company, is navigating market volatility amidst strategic developments, with its stock price experiencing significant fluctuations due to challenges in maintaining its market position and revenue streams.

Aquestive Therapeutics reported a modest 1.49% revenue increase in Q1 2025, but faces ongoing challenges in achieving profitability with a projected loss per share of -$0.663 for the current fiscal year.

Aquestive Therapeutics Inc. is a pharmaceutical company focused on central nervous system diseases, navigating challenges and opportunities in the industry with a commitment to innovation and patient care.